Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IFN lozenge, IFN-alpha lozenge, Veldona, low dose IFN lozenge
Interferon-alpha · 4 trials · 7 indications
A patient with a 75% or greater decrease in total OU for three visits was considered a "sustained responder".
Time to resolution of influenza symptoms defined as all flu symptoms scored as \<=1 and change in viral load (RT-PCR).
Number of subjects in each group meeting the definition of influenza-like illness during treatment (i.e. those subject reporting one or more moderate to severe cold/flu symptoms during the treatment period).
Number of subjects with a 75% or greater decrease from baseline to week 24 in total oral wart area
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | (placebo)0 IU IFNa |
| 2 | EXPERIMENTAL | (Veldona)500 IU IFNα bid |
| 3 | EXPERIMENTAL | (Veldona)1000 IU IFNα bid |
| Interferon-alpha | EXPERIMENTAL | Interferon-alpha 150 IU lozenges bid for 5 days |
| maltose | PLACEBO_COMPARATOR | maltose 200 mg maltose lozenges bid for 5 days |
| placebo | PLACEBO_COMPARATOR | placebo lozenges |
| IFN lozenges | EXPERIMENTAL | 500 IU Interferon-alpha lozenges for oral dissolution |
| placebo lozenges | PLACEBO_COMPARATOR | 200 mg lozenges containing anhydrous crystalline maltose |
| Name | Type | Description |
|---|---|---|
| Veldona, | BIOLOGICAL | Very low dose oral natural human interferon alpha lozenges |
| Interferon-alpha | DRUG | 150 IU lozenges bid for 5 days |
| Oseltamivir | DRUG | 75 mg capsules bid for 5 days |
| maltose | OTHER | 200 mg maltose lozenges bid for 5 days |
| placebo | OTHER | placebo lozenges for oral dissolution taken once daily for 16 weeks |
Inclusion Criteria: * Is a male or a non-pregnant, non-lactating female. * Has a history and clinical presentation consistent with a diagnosis of Behçet's Disease and meets International Study Group criteria (Appendix B). * Has a history of oral ulcers for at least 12 months. * Has a history of mon...
Interferon-alpha is an investigational small molecule being developed by Ainos, Inc. for the treatment of Influenza A Virus Infection, Upper Respiratory Tract Infections, and Papillomatosis. It is currently in Phase 2 clinical development for these infectious disease indications.
Interferon-alpha is a small molecule that belongs to the interferon class of drugs. It works by modulating the immune system's response to viral infections, though the specific molecular target has not been disclosed in the available clinical trial information.
Interferon-alpha is being developed by Ainos, Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol AIMD on the NASDAQ stock exchange.
Interferon-alpha is currently in Phase 2 clinical development. It has completed three Phase 2 clinical trials, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.
Interferon-alpha has completed three Phase 2 clinical trials. These include NCT00454181 for oral warts in HIV+ patients, NCT00895947 for prevention of winter colds and flu, and NCT01146535 for influenza treatment in combination with oseltamivir. All trials have been completed.
Interferon-alpha is a specific type of interferon, a class of proteins with antiviral and immunomodulatory properties. While it shares the general mechanism of interferons, it is a distinct drug being developed by Ainos, Inc. for specific indications.